However, it should be noted that patients with decompensated liver cirrhosis (Child-Pugh classes B and C) are not ideal candidates for ACE inhibition due to significantly lower arterial blood pressure and increased risk of hepatorenal syndrome–associated renal dysfunction (14, 47, 48). The gene discussed is ACE; the disease is cirrhosis of liver.